Pierre Fenaux
皮埃尔·费诺
MD, PhD
Professor and Head of Senior Hematology Service血液科主任及教授
👥Biography 个人简介
Pierre Fenaux is one of Europe's most eminent MDS specialists, having led transformative trials of azacitidine and lenalidomide in MDS. His work established azacitidine as the standard of care for higher-risk MDS and elucidated the biology of del(5q) syndromes.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Azacitidine in Higher-Risk MDS
Led the AZA-001 phase III trial demonstrating azacitidine improved overall survival versus conventional care in higher-risk MDS, establishing it as the international standard of care.
del(5q) MDS Biology and Lenalidomide
Conducted foundational studies on lenalidomide in del(5q) MDS, demonstrating cytogenetic and hematologic responses and defining this subset's unique therapeutic sensitivity.
Representative Works 代表性著作
Efficacy of Azacitidine Compared with Conventional Care Regimens in Higher-Risk MDS (AZA-001)
Lancet Oncology (2009)
Landmark trial demonstrating azacitidine improved median overall survival from 15 to 24 months versus conventional care, redefining treatment standards for higher-risk MDS.
Lenalidomide in Lower-Risk Myelodysplastic Syndromes with del(5q)
New England Journal of Medicine (2011)
MDS-004 trial confirming lenalidomide's cytogenetic and transfusion-independence benefit in del(5q) MDS, supporting its standard use in this subtype.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 皮埃尔·费诺 的研究动态
Follow Pierre Fenaux's research updates
留下邮箱，当我们发布与 Pierre Fenaux（Hôpital Saint-Louis, AP-HP / Université Paris Cité）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment